Trials / Completed
CompletedNCT02935725
A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males
A Phase 1, Single-centre, Double-blind, Placebocontrolled Crossover Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Male Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Autifony Therapeutics Limited · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
A Phase 1, Single-centre, Double-blind, Placebo controlled Crossover Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Male Participants
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Low dose AUT00206 800mg | |
| DRUG | High dose AUT00206 2000 mg | |
| DRUG | Placebo | |
| DRUG | Ketamine | |
| OTHER | Saline |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2017-11-01
- Completion
- 2017-11-01
- First posted
- 2016-10-17
- Last updated
- 2017-11-27
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02935725. Inclusion in this directory is not an endorsement.